UK Biomanufacturing Team to Spearhead Development of Advanced Controls to Accelerate Drug and Vaccine Manufacturing
Retrieved on:
Thursday, July 29, 2021
Biotechnology, General Health, Infectious diseases, Health, Pharmaceutical, Biotechnology, Bioprocess, Pharmaceutical industry, Natural sciences, Manufacturing, National Health Service, Medication, NHS Scotland, Articles, Nature, CPI, Pall Corporation, Biopharm Services, SCIEX, BiologIC Technologies, CPI, PALL CORPORATION, BIOPHARM SERVICES, SCIEX, BIOLOGIC TECHNOLOGIES
The project, worth a total of 3.1million, including equipment contributions, has received support from Innovate UK, to platform this advanced technology.
Key Points:
- The project, worth a total of 3.1million, including equipment contributions, has received support from Innovate UK, to platform this advanced technology.
- This will ultimately reduce manufacturing costs and improve product quality, lowering costs to the NHS, and increasing access to life-changing drugs for patients.
- The continuous bioprocessing module will be linked to the BioSolve Process cost modelling platform of lead partner Biopharm Services.
- By clarifying the business case using BioSolve Process and actively sharing practical control strategies, the consortium will advance UK biopharmaceutical manufacturing.